Brightstar Resources (BTR:AU) has announced Updated Goldfields Feasibility Study

Download the PDF here.

Brightstar Resources (BTR:AU) has announced Updated Goldfields DFS Presentation

Download the PDF here.

Chen Lin of Lin Asset Management explains what’s behind silver’s move into the triple digits, weighing in China’s key role in the market.

He also talks about taking profits in silver, and shares his outlook for gold and critical minerals.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

John Feneck, portfolio manager and consultant at Feneck Consulting, weighs in on recent silver and gold price milestones and shares his next targets.

He also discusses stocks he’s watching in sectors like silver, gold and ‘special situations.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

Gold and silver’s historic price rises are raising questions about the broader state of the world.

For Mark Moss, the surges reflect a deeper breakdown of trust in sovereign currencies.

“The real driver is not inflation,” the investor and commentator emphasized during a fireside chat at the recent Vancouver Resource Investment Conference. “The real driver is trust.”

Many investors remain focused on short-term price signals and conventional indicators, such as real interest rates, while overlooking deeper forces shaping capital allocation. According to Moss, the current state of the market favors long-term allocation. In his view, conviction — not timing — should guide investment decisions.

“You can’t borrow someone else’s conviction,” he said. “You have to start to learn to build your own thesis, and then you have to learn to look to find things that either confirm that thesis or deny that thesis.”

Precious metals are continuing a powerful price rally that began last year.

The gold price broke above US$5,500 per ounce for the first time on Wednesday (January 28), while silver broke through the triple-digit level last week and has continued rising, passing US$119 per ounce.

These moves are happening amid escalating geopolitical and policy uncertainty. However, Moss cautioned against focusing on shorter-term gold and silver price drivers, instead pointing to what he described as a fundamental dilemma facing governments with rising debt burdens — a dynamic he said is reshaping global capital flows.

Referencing comments by hedge fund founder Ray Dalio at the World Economic Forum in Davos, Switzerland, Moss described a “rock and a hard place” scenario. Governments face a choice between allowing debt crises that risk defaults and asset collapses, or continuing to expand money supply in ways that erode purchasing power.

“Either they have option one, the rock, which is a sovereign debt crisis, asset prices plunging — that’s what everybody’s kind of thinking. The markets are going to crash. My home values, my retirement value is going to crash. But the problem with that is they lose everything. They get wiped out, they have massive civil unrest,’ he said.

“And then the hard place is they can print the money. And so of course, they’ll always choose to bring the money.’

As a result, large institutional and sovereign investors face losses whether governments default or inflate, prompting a reassessment of traditional reserve assets. Moss said gold has emerged as one response to that reassessment, alongside broader interest in commodities and critical minerals. He further pointed to continued central bank gold buying as a signal that confidence in fiat currencies and the post-war financial order is weakening.

According to the World Gold Council, central banks have been purchasing gold at record levels in recent years.

Moss cited Poland as a notable example, describing it as a close US ally that has nonetheless been accumulating gold aggressively. Other large entities are following the same strategy — Tether, the world’s largest stablecoin issuer, recently revealed that part of its long-term plan is the stockpiling of gold in a Swiss bunker.

Gold’s rally is built on a strong multi-year advance. After starting 2025 at around US$2,640, the price had climbed to roughly US$3,200 by April before trading in a narrow range through the summer.

Momentum returned in late August, carrying gold above US$4,300 by mid-October. While the price briefly dipped below US$4,000 during a subsequent pullback, the retracement proved shallower and shorter than many market watchers expected. Gold resumed its ascent in mid-November and accelerated sharply toward the end of 2025.

Right now, the status quo is in favor of precious metals.

Regardless, Moss returned to the importance of taking a long-term perspective, stating that investors who fixate on short-term price moves risk missing the broader shift underway as trust dynamics change across the global economy.

“If you’re trying to understand why the price of gold dipped from US$5,000 and now it’s US$4,800, I can’t really help you with that,” Moss said. “But we understand the direction that’s at hand.”

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Seegnal Inc. (TSXV: SEGN) (‘Seegnal‘ or the ‘Corporation‘), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults — a significant clinical and financial challenge across long-term care (LTC), and risk-based care models.

The findings, presented at the CALTCM Summit for Excellence (October 23–25, 2025), provide direct evidence that prescribing decisions — when measured and governed at scale — represent one of the largest untapped levers for cost avoidance and quality improvement in senior care.

A DIRECT HIT ON ONE OF LTC’S MOST EXPENSIVE PROBLEMS

Falls are a significant cause of hospitalization, litigation exposure, staffing strain, and avoidable costs in LTC facilities.

Seegnal analyzed real-world prescribing behavior related to alpha-blocker use in older women, a known contributor to falls, using live clinical workflows rather than retrospective claims data.

The study population included 124,461 female patients aged 70 or older

Results from a three-month deployment:

• 5,088 real prescribing alerts analyzed
• 35% of cases resulted in treatment modification (~1,750 patients)
• High rates of temporary and repeated overrides, signaling systemic risk patterns rather than one-off clinical judgment

The implication for LTC operators is clear: fall risk is being created upstream at the prescription level — and can be mitigated before it becomes an admission, incident report, or lawsuit.

WHY THIS MATTERS FOR PAYERS AND LONG-TERM CARE NETWORKS

Unlike traditional clinical decision support tools that fire alerts and stop there, Seegnal exposes how organizations actually prescribe, where risk accumulates, and where policy gaps exist.

For LTC operators and payers, this enables:

• Reduction in fall-related hospitalizations.
• Lower pharmacy spends and medication burden.
• Improved quality metrics and star ratings.
• Meaningful risk reduction without workflow disruption.
• Actionable data to support value-based contracts.

The results of the study are encouraging as they demonstrate the possibility of cost avoidance + capacity creation driven by real prescribing behavior.

FROM ALERTS TO PRESCRIPTION GOVERNANCE

The CALTCM findings highlight a broader structural issue in senior care: clinicians often recognize medication risk, but organizations often lack the governance layer to turn that insight into sustained, system-wide improvement.

Seegnal aims to fill that gap by acting as the Prescription Operating System for healthcare organizations — enabling them to:

• Track prescribing risk across facilities and populations.
• Distinguish justified clinical exceptions from unsafe patterns.
• Set, monitor, and refine medication policies at scale.
• Align clinical safety with financial accountability.

MANAGEMENT COMMENTARY

‘In long-term care, falls are not just clinical events — they are balance-sheet events,’ said Elad Bibi-Aviv, Chief Executive Officer of Seegnal.

‘What this data shows is that prescribing decisions are one of the few levers organizations can control before costs explode. Seegnal gives LTC operators and payers visibility and control where it actually matters — upstream.’

‘Organizations don’t need more alerts. They need governance, measurement, and proof of value. That is exactly what Seegnal was built to deliver.’

‘Technology is essential, but the real impact on patient outcomes depends on implementation and culture. Seegnal not only integrates seamlessly into workflows but also flags non-rational medication use at the institutional level, enabling management to drive clinical excellence,’ said Dr. Shiri Guy-Alfandary, VP Clinical & Product.

BUILT FOR THE LONG-TERM CARE MARKET: DATA FIRST, FAST VALUE

Seegnal is actively opening Long Term Care engagements through a data-first model:

• Read-only clinical data access (no workflow change).
• Rapid identification of high-cost prescribing patterns.
• Clear clinical and economic KPIs.
• Scalable deployment once value is proven.

This approach aligns directly with the needs of:

• Multi-facility LTC operators.
• Payers.
• Risk-bearing provider networks.

ABOUT THE CLINICAL EVIDENCE

The findings were presented in ‘Reducing Inappropriate Use of Alpha-blockers in Geriatric Patients’ by Dr. Hen Popilski and Dr. Shiri Guy-Alfandary, PharmD, Seegnal, based on real-world prescribing data from routine clinical practice.

The findings and conclusions referenced in this press release are derived from Seegnal’s internal studies. These findings are preliminary in nature, may be based on assumptions and methodologies developed for internal use, and have not been independently audited, verified, or peer‑reviewed. The information is provided solely for general informational purposes.

About Seegnal

Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world – Adverse Drug Effects (ADEs). Seegnal’s Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal’s SaaS technology exclusively integrates, at the point-of-care, unique patient-specific data such as lab results, vital signs, ECG, smoking status, allergies, food interactions, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Patients enjoy more tailored medication and improved safety, leading to better quality of life, with precision alerts reaching up to 98% accuracy. Institutions have reported reductions in admissions, medication consumption, and significant time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in Israel (where the Ministry of Health recently adopted Seegnal’s patient-specific standard as the new standard in governmental hospitals), the United Arab Emirates, the United Kingdom, the United States, and Poland. The platform is currently a ‘standard of care’ system for over 15,000 clinicians in Israel, used daily for prescribing medications.

See www.seegnal.com.

Cautionary Note Regarding Forward-Looking Information

This press release contains ‘forward-looking information’ or ‘forward-looking statements’ within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the ‘About Seegnal’ section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as ‘anticipate’, ‘believes’, ‘estimates’, ‘expects’, ‘intends’, ‘may’, ‘should’, ‘will’ or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements concerning the application of Seegnal’s findings and conclusions, and any benefit, implied or express, that may be realized by Seegnal or its clients. These statements, including the findings discussed herein, are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to Seegnal’s public filings with applicable securities regulators for additional information regarding risk factors and other disclosures.

Seegnal cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products as well as other risks and uncertainties, including those described in Seegnal’s filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source